Nexium Tablets

/ Astra Zeneca

Gastroesophageal Reflux Disease (GERD)
– treatment of erosive reflux esophagitis:
40 mg once daily for 4 weeks.
An additional 4 weeks treatment is recommended for patients in whom esophagitis has not healed or who have persistent symptoms.
– long-term management of patients with healed esophagitis to prevent relapse:
20 mg once daily.
– symptomatic treatment of gastroesophageal reflux disease (GERD):
20 mg once daily in patients without esophagitis. If symptom control has not been achieved after four weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using an on-demand regimen taking 20 mg once daily, when needed. In NSAID treated patients at risk of developing gastric and duodenal ulcers, subsequent
symptom control using an on demand regimen is not recommended.
Adults
In combination with an appropriate antibacterial therapeutic regimen for the eradication of Helicobacter pylori and
– healing of Helicobacter pylori associated duodenal ulcer and
– prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers:
20 mg NEXIUM with 1 g amoxicillin and 500 mg clarithromycin, all twice daily for 7 days.
Patients requiring NSAID therapy:
– healing of gastric ulcers associated with NSAID therapy: The usual dose is 20 mg once daily. The treatment duration is 4-8 weeks.
– prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk: 20 mg once daily.
Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers:
40 mg once daily for 4 weeks after i.v. induced prevention of rebleeding of peptic ulcers.
Children and adolescents: Safety and effectiveness in pediatric patients have not been established.
Impaired renal function: Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patients with severe renal insufficiency, such patients should be treated with caution.
Impaired hepatic function: Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, a maximum dose of 20 mg NEXIUM should not be exceeded.
Elderly: Dose adjustment is not required in the elderly.

Gastroesophageal Reflux Disease (GERD): Treatment of erosive reflux esophagitis. Long-term management of patients with healed esophagitis to prevent relapse. Symptomatic treatment of GERD. Helicobacter pylori: In combination with appropriate antibacterial therapeutic regimens for the eradication of helicobacter pylori. Healing of helicobacter pylori associated duodenal ulcer. Prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.Patients requiring NSAID therapy.

Known hypersensitivity to esomeprazole, substituted benzimidazoles or any other constituents of the formulation. Esomeprazole should not be administrated with nelfinavir. Patients with rare hereditary problems of fructose
intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

See prescribing information for full details.

Headache, abdominal pain, diarrhoea and nausea are among those adverse reactions that have been most commonly reported in clinical trials (and also from post-marketing use). In addition, the safety profile is similar for different formulations, treatment indications, age groups and patient populations.
No dose-related adverse reactions have been identified.
See prescribing information for full details.

See prescribing information for full details.